AnaptysBio, Inc.
$50.95
▲
1.67%
2026-04-21 05:18:00
www.anaptysbio.com
NMS: ANAB
Explore AnaptysBio, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$1.46 B
Current Price
$50.95
52W High / Low
$73.3 / $17.11
Stock P/E
—
Book Value
$1.33
Dividend Yield
—
ROCE
14.7%
ROE
-24.49%
Face Value
—
EPS
$-0.46
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
104
Beta
0.41
Debt / Equity
781.08
Current Ratio
9.07
Quick Ratio
9.07
Forward P/E
-19.82
Price / Sales
8.59
Enterprise Value
$1.99 B
EV / EBITDA
41.16
EV / Revenue
8.5
Rating
Strong Buy
Target Price
$79.91
EPS Forecast (FY)
—
Pros
- Efficient use of capital employed.
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Strong operating margin profile.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | ImmunityBio, Inc. | $8.01 | — | $8.28 B | — | -58.17% | 71.02% | $12.43 / $1.83 | $-0.49 |
| 2. | ADMA Biologics, Inc. | $10.88 | 17.68 | $2.6 B | — | 34.51% | 35.56% | $25.67 / $7.21 | $2.01 |
| 3. | GT Biopharma, Inc. | $0.37 | — | $11.72 M | — | -214.65% | -13.77% | $3.85 / $0.35 | $0.23 |
| 4. | UroGen Pharma Ltd. | $24.92 | — | $1.21 B | — | -81.06% | 268.63% | $30 / $3.42 | $-2.18 |
| 5. | INmune Bio Inc. | $1.49 | — | $39.61 M | — | -128.97% | -1.65% | $11.64 / $1.09 | $0.89 |
| 6. | NovaBay Pharmaceuticals Inc | $1.4 | — | $51.92 M | 0% | -96.1% | 190.01% | $99.75 / $1.11 | $-0.92 |
| 7. | Scholar Rock Holding Corporation | $47.8 | — | $5.49 B | — | -110.26% | -1.23% | $51.62 / $27.07 | $2.26 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 108.25 M | 76.32 M | 22.26 M | 27.77 M | 43.11 M | — |
| Operating Profit | 66.9 M | 34.7 M | -26.17 M | -27.54 M | -9.67 M | — |
| Net Profit | 49.61 M | 15.11 M | -38.63 M | -39.33 M | -21.78 M | — |
| EPS in Rs | 1.73 | 0.53 | -1.34 | -1.37 | -0.76 | — |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 234.6 M | 91.28 M | 17.16 M | 10.29 M |
| Operating Profit | 47.9 M | -114.95 M | -157.07 M | -115.15 M |
| Net Profit | -13.23 M | -145.23 M | -163.62 M | -128.72 M |
| EPS in Rs | -0.46 | -5.05 | -5.69 | -4.48 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 364.39 M | 483.83 M | 452.39 M | 610.38 M |
| Total Liabilities | 327.19 M | 412.97 M | 364.29 M | 348.28 M |
| Equity | 37.21 M | 70.87 M | 88.1 M | 262.1 M |
| Current Assets | 350.25 M | 431.88 M | 406.83 M | 447.2 M |
| Current Liabilities | 38.62 M | 45.43 M | 37.44 M | 26.05 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | 19.7 M | -135.34 M | -120.8 M | -73.59 M |
| Investing CF | 228.03 M | 95.4 M | 144.75 M | -394.85 M |
| Financing CF | -132.61 M | 127.05 M | -59.3 M | 44.02 M |
| Free CF | 19.61 M | -135.69 M | -121.61 M | -73.95 M |
| Capex | -0.09 M | -0.36 M | -0.81 M | -0.36 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue Growth % | 157.01% | 432.03% | 66.78% | — |
| Earnings Growth % | 90.89% | 11.24% | -27.11% | — |
| Profit Margin % | -5.64% | -159.1% | -953.66% | -1251.33% |
| Operating Margin % | 20.42% | -125.93% | -915.5% | -1119.41% |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | 29.52% | -101.6% | -834.43% | -1023.2% |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.